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Abstract  
Purpose 
Smoking is a major cause of lung cancer and continued smoking may compromise 
treatment efficacy and quality of life (HRQoL) in patients with advanced lung cancer. 
Our aims were to determine i) preference for treatments which promote quality over 
length of life depending on smoking status, ii) the relationship between HRQoL and 
smoking status at diagnosis (T1), after controlling for demographic and clinical 
variables and iii) changes in HRQoL 6 months after diagnosis (T2) depending on 
smoking status. 
Methods 
296 patients with advanced lung cancer were given questionnaires to assess HRQoL 
(EORTC-QLQ-C30), time-trade off for life quality versus quantity (QQQ) and 
smoking history (current, former or never smoker) at diagnosis (T1) and six months 
later (T2). Medical data were extracted from case records. 
Results 
Questionnaires were returned by 202 (68.2%) patients at T1 and 114 (53.3%) at T2. 
Patients favoured treatments that would enhance quality of life over increased 
longevity.  Those who continued smoking after diagnosis reported worse HRQoL 
than former smokers or those who never smoked.  Smoking status was a significant 
independent predictor of coughing in T1 (worse in smokers), and Cognitive 
Functioning in T2 (better in never-smokers).  
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Conclusions 
Smoking by patients with advanced lung cancer is associated with worse symptoms 
on diagnosis and poorer HRQoL for those who continue smoking. The results have 
implications to help staff explain the consequences of smoking to patients. 
 
Keywords: Lung cancer, smoking, smoking cessation, quality of life 
 
Relevance of manuscript: This paper assesses the relationship between smoking 
and HRQoL in patients with advanced lung cancer. It shows that smoking is 
associated with worse symptoms on diagnosis and poorer HRQoL for those who 
continue smoking. This knowledge can be used when smoking status and smoking 
cessation are discussed with patients to provide positive encouragement of the 
benefits of quitting. 
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Introduction  
Lung cancer accounts for 27% of cancer deaths [1]. Five-year survival rates range 
from 52% for lung cancer patients with localised disease to 4% for those with distant 
metastases [1]. Patients often are elderly (median age 70 years), diagnosed at a late 
stage, and have complex medical histories and co-morbidities [2]. Patients with 
advanced lung cancer typically have troublesome symptoms. This, compounded with 
the added burden of side effects from chemotherapy and radiotherapy, can 
adversely impact their quality of life. 
When discussing treatments for advanced lung cancer, both survival benefits and 
health related quality of life (HRQoL) should be considered [3]. HRQoL captures the 
broader consequences of illness for cognitive, social and emotional functioning in 
addition to physiological effects of illness and treatment [4]. Symptom palliation and 
HRQoL are very important to patients [5] and those who are older with incurable 
disease may prioritise quality over length of survival [6, 7]. 
Over 86% of lung cancers are attributed to smoking [8]. In early stage lung cancer, 
continued smoking is associated with greater post-operative morbidity [9] and a two-
fold greater risk of death [10]. In more advanced disease, smoking is associated with 
radiation-induced pneumonitis [11], greater difficulty in administering chemotherapy 
due to worse baseline symptoms [12], and decreased treatment efficacy, through 
mechanisms such as altered pharmacokinetics [13]. Half of patients who quit 
smoking begin again after potentially curative surgery [14], illustrating how difficult it 
can be to quit even when motivation to do so is substantial.  
Lung cancer patients have reported feeling more judged than breast or prostate 
cancer patients and are most likely to acknowledge their own behaviours as a causal 
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factor in disease onset [15]. Evidence suggests that perceived stigma is not 
constructed by patients who perhaps feel guilty or shameful themselves, but reflects 
opinions which are evident in the general population [16, 17] and within health care 
professions [18, 19]. For lung cancer patients, these opinions appear to develop 
because of the strong association between disease onset and smoking regardless of 
the patients’ personal history of smoking [18].   
Where the patient perceives stigmatisation they may feel that family, friends, and 
medical staff are less supportive than they could be, to the detriment of HRQoL, in 
turn, affecting treatment decisions. Smoking cessation is one intervention which is 
under direct control of the patient and which could have a positive impact on their 
outcomes leading a patient who quits to feel empowered [20]. Equally, those who 
have never smoked, or continue to smoke may feel more nihilistic about their 
outcomes. In these situations, smokers may have different opinions about treatment 
options that benefit quality over length of survival compared with never smokers. 
Given the established links between smoking and lung cancer, newly diagnosed 
patients who smoke might be especially motivated to quit, but little is currently known 
about the implications of smoking cessation for HRQoL in advanced lung cancer [21, 
22]. 
 We therefore undertook a longitudinal study to determine:  
i) preference for treatments which promote quality over length of life depending on 
smoking status 
ii) relationship between HRQoL and smoking status at diagnosis (T1), controlling for 
demographic and clinical variables 
iii) changes in HRQoL 6 months after diagnosis (T2) depending on smoking status 
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Materials and methods  
Patients 
Patients (>18 years old) with a pathological diagnosis of advanced lung cancer were 
recruited from the North Trent Cancer Network, UK between December 2009 and 
January 2012. Inclusion criteria were diagnosis within 12 weeks, unsuitable for 
radical treatment with radiotherapy or surgery, and clinician-estimated survival of 
greater than six months. The pathology could be either non-small cell lung cancer 
(NSCLC) or small cell lung cancer (SCLC). North Sheffield Research Ethics 
Committee approved the study and the work was performed in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki. All patients were 
treated according to local guidelines. 
Study procedures 
Clinicians approached eligible patients with verbal and written information about the 
study and obtained signed consent.  Patients completed questionnaires at home, or 
in clinic with assistance from a researcher. Assistance was only given with reading 
and completing the form, not in how to interpret the questions. Six months after 
recruitment (T2), surviving patients were sent questionnaires by post. On both 
occasions, reminders were sent to non-responders after two weeks. Throughout the 
study, patients wishing to pursue smoking cessation were supported by lung cancer 
clinical nurse specialists. There was no standard practice on smoking cessation 
services provided by the clinical team so the options were discussed with patients 
and individual plans designed. 
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Quantitative measures 
The EORTC-QLQ-C30 questionnaire was used to evaluate cancer-related HRQoL 
[23]. This yields a Global HRQoL score, five function scales (physical, role, 
emotional, cognitive, and social functioning), three symptom scales (fatigue, pain, 
nausea and vomiting), and six single item symptom scores (dyspnoea, insomnia, 
appetite loss, constipation, diarrhoea, and financial difficulties). Higher scores for 
Global HRQoL and function scales indicate better HRQoL. High symptom scores 
indicate worse outcomes. The EORTC QLQ-LC13 lung cancer module [24] 
comprises one scale (dyspnoea) and nine single item symptom scores and was used 
to assess disease-specific HRQoL. The 8-item Quality-Quantity Questionnaire 
(QQQ) [6] was used to determine preferences for quality and length of life. This 
includes eight statements about accepting life-prolonging treatments at the expense 
of life quality or vice versa (for example, ‘to live a bit longer I would try any treatment 
that might help’, and ‘I can imagine some side-effects being so bad that I would 
refuse treatment, even if it meant a shorter life’). Each statement is followed by a five 
point Likert scale. Responses are summed to produce two scales: a preference for 
quality of life (‘Q’) and a preference for length of life (‘L’). A high score on the Q scale 
indicates a high value for quality of life over length and a high score on L indicates a 
preference for length of life over quality. The QQQ has demonstrated validity for use 
with cancer patients: internal reliability scores range from 0.68-0.75 for Quality and 
0.67-0.79 for Length [6, 7, 25].  
Patients provided demographic information by completing self-report questionnaires. 
Smoking status was self-categorised as never (smoked less than five cigarettes 
ever), former (‘I used to smoke but have now given up) or current (‘I am a smoker’). 
At T1 information about gender, date of birth, diagnosis, Performance Status (PS) 
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[26], treatment (chemotherapy, radiotherapy, other), and previous or long-term 
health problems were obtained from self-report questionnaires. At T2, toxicity 
outcomes [27] (number of events rated severe and undesirable) (3) or life-
threatening or disabling (4)) and number of chemotherapy cycles were recorded by 
retrospective extraction of data from the notes. 
Statistical analysis 
Analyses were conducted using SPSS 20.0 [28]. Skewed variables (QQQ scales (T1 
and T2) and HRQoL outcomes (T1 and T2) were log-transformed where necessary. 
Attrition analyses were conducted to determine differences between those who 
responded at T1 but not T2 (non-deceased) and those who replied to both 
questionnaires.  Differences in age, gender, PS and diagnosis were assessed with 
Chi-square and independent samples t-tests for number of toxic incidences, T1 
HRQoL (all outcomes), and T1 QQQ.   
Mixed ANOVA was used to examine relationships between QQQ and smoking status 
and multiple regression models to predict HRQoL. HRQoL outcomes associated with 
smoking status were used as dependent variables in a regression model. T-tests, 
correlations, and ANOVAs (with Tukey post-hoc analysis) determined other baseline 
variables associated with HRQoL or smoking which may be potential confounds, 
which were then included in regressions at step 1. Step 2 examined the additional 
effect of the smoking variables after the baseline effects were taken into account. All 
analyses were conducted separately at T1 and T2. 
Smoking status was dummy coded in regression models.  Initially ‘never smoked’ 
was the reference for comparison with current and former smokers. Models were 
repeated with current smokers as the reference category to provide comparison 
between current and former smokers. PS was dummy coded and entered into the 
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regression model, with PS 0 (full functioning) as the reference value. Multiple 
regression models included only participants with complete data on all predictor 
variables. The resulting number of participants included in each model is shown in 
Tables 2 and 3. 
For ease of interpretation, non-standardised regression coefficients (b) are reported 
for categorical variables entered into regression models (smoking status, PS, 
employment status (1=not retired), sex (1=female)). Standardised regression 
coefficients () are reported for continuous variables.   
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Results  
Sample description 
The flow of patients through the study is shown in Figure 1. In total 641 possible 
patients were identified from medical records and 304 consented to take part. 309 
were considered inappropriate to approach or ineligible by the clinician, for example 
if they were too unwell, had a predicted life expectancy less than six months, or were 
highly distressed by their diagnosis. Eight subsequently withdrew leaving a final 
sample of 296. Participants did not differ in age, gender, PS or diagnosis (NSCLC or 
SCLC) from those (n=94) who consented but did not respond.  Median interval from 
diagnosis was 5.14 weeks (range 0.9-12.0 weeks) and did not differ by smoking 
status (F(2,194)=2.05, p=.09). At T1, there were 20 (10%) never-smokers, 45 
(22.5%) current smokers and 135 (67.5%) former smokers, two participants did not 
classify their smoking behaviour and are excluded from analyses. One patient 
resumed smoking between T1 and T2.  Participants were typically white (99.5%), 
male (57.7%), aged 68 years (range 43.2-85.5 years), reported no formal 
educational qualifications (58.9%) and had a PS of 1 (64.4%). Most patients were 
diagnosed with NSCLC (73.5%), 49.5% had distant metastases and 77.0% received 
chemotherapy. Never-smokers were more often older, female, partnered and more 
educated, with fewer previous medical conditions (PMC) than current or former 
smokers and fewer long-term health problems (LTHP) than former smokers. 
Baseline characteristics of patients are shown in Table 1. T2 demographic and 
medical variables were similar to T1. There were no significant differences on key 
variables between those who responded at T1 but not T2 (non-deceased) and those 
who replied at both times. 
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Data were also collected on cause of death and were as follows: death was directly 
attributable to the cancer in 63 cases; deaths from anticancer treatment - 2 (1 bowel 
perforation secondary to erlotinib, 1 neutropenic sepsis); death for other reasons - 16 
(ischaemic stroke 1, pneumonia 9, pulmonary embolus 2, heart failure 1, pulmonary 
fibrosis 1, ruptured abdominal aortic aneurysm 1, sepsis 1); and cause of death was 
unknown in 1 case. 
i) Preference for quality versus length of life by smoking status 
At T1 and T2, there was a significant preference for quality over length of life (T1: 
quality=2.52(.29), length=1.85(.46); F(1,182)=98.201, p<.001; T2: quality=2.53(.30), 
length=1.91(.47), F(1,99)=38.1, p<.001), but no effect of smoking status (T1: 
F(2,182)=.27, p=.77; T2: F(2,99)=.60, p=.55) and no interaction between smoking 
status and time (T1: F(2,182)=1.41, p=.32; T2: F(2,99)=.75, p=.48). 
ii) Associations between HRQoL and smoking status at baseline.  
There was a significant association between smoking status and physical functioning 
(F(2,196)=3.52, p=.03), with never-smokers (76.00 [22.93]) reporting significantly 
better physical functioning than former smokers (61.86 [22.93], p=.02). Coughing 
was also associated with smoking status (F(2,196)=5.21, p=.01), with current 
smokers (50.00[25.42]) reporting more coughing than former smokers (35.62 [27.79], 
p=.007). There were no other significant relationships between smoking status and 
HRQoL.  
Chemotherapy was not included in regression modelling as all current smokers 
received chemotherapy, violating the multicollinearity assumption. 
Physical functioning 
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Physical functioning was significantly associated with QQQ Length (r=-.21, p=.003) 
and PS (F(3,188)=9.30, p<.001) which were entered into the regression model along 
with correlates of smoking status. Clinical and demographic variables explained 24% 
of variance in physical functioning at step 1, but smoking status was not a significant 
additional predictor (step 2, Table 2).   
Coughing 
Male gender was associated with coughing (t(185.19)=2.25, p=.03) (equal variance 
not assumed) and was included in the regression model as a covariate.  Being male 
and a current smoker (compared to never and former smokers) were independently 
associated with worse coughing (Table 2).   
iii) Change in HRQoL at Q2 predicted by smoking status. 
At T2, smoking status was associated with cognitive functioning (F(2,110)=5.22, 
p=.01), social functioning (F(2,110)=4.32, p=.02), and fatigue (F(2,109)=4.54, p=.01).  
Never-smokers (99.54[1.71]) had better cognitive functioning than former smokers 
(98.14[1.35], p=.008) and current smokers (97.99[1.48], p=.007). Former smokers 
reported better social functioning (63.93[28.19]) than current smokers (45.40[30.50], 
p=.01) and less fatigue (48.93[27.31] and 66.81[26.81], p=.01). There were no other 
significant relationships between smoking status and HRQoL. 
At T2, smoking status was associated with age (F(2,111)=4.19, p=.02), employment 
status (2(2)=6.96, p=.03) and number of PMCs (F(2,104)=3.29, p=.04).  These 
variables were included as confounders in multiple regressions to predict fatigue, 
cognitive and social functioning. 
Cognitive functioning  
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LTHP (r=-.19, p=.04), T1 cognitive functioning (r=.30, p<.01) and T1 fatigue (r=-.27, 
p<.01) were significantly associated with T2 cognitive functioning and were included 
in this regression model at step 1, which significantly predicted T2 cognitive 
functioning (Table 3). The addition of smoking status at step 2 significantly increased 
the amount of variance explained (R2Change=.08, p=.02). Former smokers (B=-1.47, 
p=.005) and current smokers (B=-1.43, p=.014) both independently predicted worse 
T2 cognitive functioning, after controlling for T1 cognitive functioning.  
Social functioning  
T1 social functioning (r=.36, p<.001), T1 fatigue (r=-.29, p<.01) and female gender 
(r=.20, p<.05) were significantly associated with T2 social functioning and were 
included in step 1.  At step 1, being female was an independent predictor of better 
social functioning (B=13.06, p=.03). Smoking status did not explain additional 
variance in the model (R2Change=.05, p=.08) (Table 3) although the specific 
comparisons indicated that former smokers had significantly better social functioning 
compared to current smokers (B=15.76, p=.03). 
Fatigue 
T1 fatigue (r=.46, p=<.01), T1 social functioning (r=-.31, p<.01), and number of toxic 
incidents (r=.24, p=.01) were significantly associated with T2 fatigue and were 
entered at step 1.  T1 fatigue was the only significant independent predictor of T2 
fatigue, at step 1 (=.46, p<.001).  At step 2 smoking status did not explain additional 
variance in the model (R2Change=.03, p=.19) (Table 3). 
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Discussion  
Our data indicate a significant preference for quality over length of life up to six 
months post-diagnosis in advanced lung cancer patients, which is a new finding 
supported by previous related literature [6, 7, 25]. Preference for quality was 
independent of smoking status. At T1, smokers had worse coughing compared with 
former or never smokers. At T2, former and current smoking was predictive of worse 
cognitive functioning than never smoking. These findings provide staff with 
information that could help them to explain the effects of lung cancer beyond 
physical symptoms and help patients make informed choices about their smoking 
behaviour to enhance their HRQoL. This understanding of a holistic effect on 
HRQOL may provide a ‘teachable moment’ for patients newly diagnosed with 
advanced lung cancer who are likely to view favourably those treatments which 
enhance life quality.  
Our data involving newly-diagnosed lung cancer patients with advanced disease 
complement previous findings by Garces et al. [29], who reported that HRQoL 
differed by smoking status in lung cancer patients who survived over a longer period 
of time (> 5 years) with smokers reporting worse HRQoL. Other studies have found 
no association between smoking and HRQoL [30, 31], but may be explained in terms 
of different patient groups. 
Furthermore, these data are consistent with previous findings that smokers present 
with more co-morbidities including respiratory and cerebrovascular disease which 
are probably attributable to chronic cigarette use [32]. It should also be noted that 
self-rated physical symptoms of pain and dysphagia are negative prognostic factors 
for survival in NSCLC [33]. The finding that those who continue to smoke after 
diagnosis report significant deterioration across some HRQoL domains could be due 
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to higher levels of co-morbidity or that tumours of never-smokers have different 
biology than in smokers. Never-smokers who develop lung cancer may be 
particularly susceptible to environmental tobacco exposure, and there is some 
evidence that this may be mediated by polymorphisms in detoxification enzymes 
[34]. This may also make these individuals more susceptible to the toxic effects of 
anticancer treatments. Tumours in never-smokers sometimes exhibit different 
molecular changes, such as EGFR activating mutations and ALK translocations [35] 
that make them more likely to respond to less toxic, outpatient targeted therapy than 
tumours in smokers.  Further, smoking itself can reduce the likelihood of success of 
systemic treatment [13].  
We conclude that continued smoking has adverse implications for both physiological 
and psychological health of lung cancer patients, raising questions of whether, and 
how, staff might encourage patients to quit. In a large scale, prospective cohort 
study, Williams et al. [36], found no statistical evidence of increased, spontaneous 
smoking cessation among those who received a cancer diagnosis compared to the 
general population. In support of this, cancer survivors have reported that they would 
find it beneficial to receive lifestyle advice from health care professionals [37]. Thus, 
diagnosis could present a ‘teachable moment’ when patients are receptive to 
smoking cessation interventions, particularly older patients with advanced disease 
[38]. In addition, the ‘teachable moment’ might be relevant to patients with other 
types of tumour where active smoking during treatment may also be detrimental in 
their situation [39]. 
The challenge to any ‘teachable moment’ may especially be among those patients 
who argue that quitting would be detrimental to their remaining HRQoL [40]. These 
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patients may benefit from data such as those reported describing physical and 
psychological symptoms typical of smokers and non-smokers undergoing treatment. 
Perhaps more than other cancers, lung cancer carries a potential blame among 
patients, their families and staff, given the strong association between smoking and 
disease onset.  Where patients do acknowledge the presence of stigma due to the 
association between smoking and lung cancer, there can be negative psychosocial 
outcomes such as depressed mood [41] and illness intrusiveness [42] which may be 
related to lower HRQoL.  In the context of this study, cognitive functioning is 
indicative of capacity for recollection and concentration.  Of course, while we do not 
know what the causal pathway is between these variables [stigma, 
mood/intrusiveness, cognitive functioning] we could postulate that perceived 
stigmatisation, and associated rumination, leads to mood disturbance and illness 
intrusiveness, subsequently decreasing cognitive functioning and HRQoL resources  
Research on the psychological theory of ‘ego-depletion’ [43] may offer a framework 
for thinking about these pathways and subsequent interventions to use in the 
teachable moment, to assist smoking cessation attempts, and improve or maintain 
HRQoL. This theory suggests that we have a limited amount of capacity to control 
our motives, intentions and behaviour and that this may be depleted by distractive, 
intrusive or negative thoughts, as well as experiences of stigmatisation [44]. It may 
be that, in trying to supress thoughts of stigmatisation, depressed mood or the 
impact of illness intrusions, patients are drawing upon their limited self-control 
resources and experiencing ego-depletion. When ego-depletion occurs, a person’s 
attention to cues which signal the need for control are compromised [45]. In the 
example of smoking cessation this may mean that people are less successful in 
controlling their impulse to smoke.   
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Strengths and limitations 
Smoking can be an emotive issue and patients with advanced lung cancer often 
have a high level of functional impairment.  Despite this, only five patients refused to 
take part and we achieved a good response rate (68% at T1), suggesting that it is 
possible to enrol patients with advanced lung cancer into studies evaluating smoking 
status and HRQoL. Strengths of this study include the longitudinal design and 
relatively large sample size compared with previous research [31, 46-48]. In using a 
cancer specific HRQoL instrument with an additional lung cancer module we gained 
a greater depth of understanding, compared with relying on a generic measure of 
HRQoL or symptom reports. Inclusion of quality versus length of life trade-offs also 
provides valuable insight into the preferences of these patients.  
Limitations include that we relied on self-reporting which may be subject to bias, 
such as common method variance effects. However, clinical practice routinely relies 
on self-report. Inevitably, and as with similar studies [30, 31, 47] we recruited only a 
small sample of never smokers (approximately 10%). However, absolute numbers of 
never smokers were small, limiting our power to make comparisons between groups. 
Our power was further compromised by unequal sample sizes across smoking 
groups. The sample size was greater than in other studies of this hard to reach 
population, but was smaller than ideal for longitudinal analyses. Loss-to-follow up 
meant that the number of observations was low for the number of independent 
variables in each model, limiting our ability to detect small effects. However, attrition 
of this sort will be inherent in a population with such poor prognosis, even over a 
relatively short six month follow-up period. It is possible that our findings may not 
represent the views of HRQoL among those who survive longer and our results 
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would benefit from replication in a larger sample. Further work would also benefit 
from adopting alternative designs. For example, a randomised controlled trial of a 
smoking cessation intervention would provide the leverage to test causal hypotheses 
about the effects of smoking on HRQoL. The current observational study is valuable 
in providing a justification for hypothesis formation in an experimental study of this 
sort.   
 
Conclusion 
These findings contribute significantly to understanding the experiences of advanced 
lung cancer patients. Newly diagnosed lung cancer patients report a significant 
preference for treatments that enhance life quality rather than increase longevity 
irrespective of their smoking status. HRQoL is dependent on smoking status at 
diagnosis and worse among those who continue to smoke. These data could help 
staff to explain the positive implications of smoking cessation for HRQoL. 
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Table 1: Patient and tumour characteristics at Q1.  
 (Frequencies (%) unless otherwise stated) 
 Current 
smokers 
(n=45) 
Quit 
smoking 
(n=135) 
Never 
smoked 
(n=20) 
Test p-
value 
Age (years)     F(2,197)=4.08 .03 
(Mean (S.D) 
Median  
(range) 
65.66a*(6.70), 
65.80  
(51-80.3) 
68.69 (7.45) 
68.00  
(44.2-85.5) 
70.79a*(9.21) 
73.25  
(43.2-81.3) 
  
      
Gender     2(2)=1.54 .46 
Male 26 (57.8) 80 (59.7) 9 (45.0)   
      
Ethnicity     - 
White 43 (100.0) 131 (99.2) 19 (100.0)   
      
Education (n=44) (n=127) (n=19) 2(2)=4.26 .12 
No formal 
educational 
qualifications 
27 (61.4) 78 (61.4) 7 (36.8)   
      
Marital status (n=44) (n=132) (n=19) 2(2)=4.80 .09 
Living as 
married / 
partner 
31 (70.5) 95 (72.0) 18 (94.7)   
Other 13 (29.5) 37 (28.0) 1 (5.3)   
      
Employment  (n=44) (n=129) (n=19) 2(2)=7.31 .03 
Retired 27 (61.4) 101 (78.3) 17 (89.5)   
Other 17 (38.6) 28 (21.7) 2 (10.5)   
      
Diagnosis      
NSCLC+ 32 (71.1) 102 (75.6) 16 (80.0) 2(2)=1.00 .61 
SCLC+ 13 (28.9) 29 (21.5) 4 (20.0)   
Not specified 0 (0.0) 4 (3.0) 0 (0.0)   
      
Staging (M)    2(2)=1.55 .46 
Localised+ 13 (28.9) 37 (27.4) 4 (20.0)   
Metastatic+ 23 (51.1) 62 (45.9) 14 (70.0)   
Not specified 9 (20.0) 36 (26.7) 2 (10.0)   
      
Treatment      
Chemotherapy (n=41) (n=115) (n=16) 2(2)=6.78 .03 
 41 (100.0) 100 (87.0) 13 (81.2)   
Radiotherapy (n=41) (n=114) (n=16) 2(2)=.99 .61 
 26 (63.4) 71 (62.3) 8 (50)   
Other (n=40) (n=115) (n=16) 2(2)=2.57 .28 
 6 (15.0) 18 (15.7) 5 (31.2)   
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Performance 
status 
(n=44) (n=127) (n=20) 2(2)=1.80 .41 
0 7 (15.9) 24 (18.9) 6 (30.0) (PS 1,2,3 grouped and 
compared with 0 for 
analysis) 
1 33 (75.0) 77 (60.6) 12 (60.0) 
2 3 (6.8) 23 (18.1) 1 (5.0) 
3 1 (2.3) 3 (2.4) 1 (5.0) 
      
Number 
previous 
cancers 
(n=45) (n=134) (n=20) F(2,197)=.02 .98 
0 37 (82.2) 114 (84.4) 17 (85.5)   
1 7 (15.6) 17 (12.6) 2 (10.0)   
2 1 (2.2) 4 (3.0) 1 (5.0)   
(mean (S.D)) .20 (.46) .19 (.46) .20 (.52)   
      
Number 
previous 
medical 
conditions 
(n=42) (n=130) (n=19) F(2,188)=6.83 <.01 
(Mean (S.D)) 1.95 (1.29)b* 2.17(1.28)a** 1.05(.71)a**b*   
      
Number long 
term health 
problems 
   F(2,197)=3.35 .04 
(Mean (S.D)) 1.49 (.17) 1.53 (1.51)a* .60 (.88)a*   
*p<.05; **p<.01.   
+ Groups that were compared for statistical analysis if not all groups were used. 
Note: Means with corresponding subscripts are significantly different from each other 
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Table 2: Q1 multiple regression analyses predicting Physical Functioning and 
Coughing. 
 Physical Functioning (n=168) Coughing (n=178) 
 Step 1 Step 2 Step 1 Step 2 
 B SE B  B SE B  B SE B  B SE B  
Age -0.25 0.27 -0.09 -0.33 0.27 -0.12 -0.44 0.32 -0.13 -0.36 0.32 -0.10 
Employment 
status  
(not retired) 
-4.22 4.59 -0.08 -3.96 4.59 -0.08 -3.71 5.58 -0.06 -5.76 5.44 -0.10 
LTHP -0.20 1.10 -0.01 -0.02 1.10 0.00 -1.37 1.39 -0.08 -1.59 1.36 -0.09 
PMC -3.55 1.31 -0.21** -3.11 1.33 -0.18** 2.87 1.69 0.14 3.12 1.68 0.15 
PS 1 -7.85 3.93 -0.17* -6.95 3.95 -0.15 - - - - - - 
PS 2 -24.18 5.65 -0.36*** -22.66 5.69 -0.34*** - - - - - - 
PS 3 -24.35 9.80 -0.19* -24.48 9.76 -0.19** - - - - - - 
QQQL -9.61 3.48 -0.20** -9.35 3.47 -0.19** - - - - - - 
Gender (Female) - - - - - - -10.09 4.00 -0.19* -9.82 3.89 -0.18 
Current smoking  
(versus never) 
- - - -9.47 5.46 -0.20 - - - 0.02 6.76 0.00 
Current smoking  
(versus never) 
- - - -10.92 6.13 -0.21 - - - 16.99 7.57 0.27* 
Quit smoking  
(versus current) 
- - - 1.45 3.78 0.03 - - - -
16.97 
4.72 -0.30*** 
 R2 =.24 (F=6.18)*** R2 =.25 (F=5.33)*** 
R2Change=.02 
R2 =.06 (F=2.31)* R2 =.13 (F=3.66)*** 
R2Change=.07** 
Note: *p<.05, **p<.01, ***p<.001 
Abbreviations: LTHP= Long term health problems, PMC=previous medical 
conditions; PSxxx = Performance status 1, 2, or 3 (dummy coded – PS 0 as 
reference value).  QQQ L=preference for treatments which increase length of life 
over quality. 
Interpretation: B = a change in dependent variable (e.g., Coughing) per unit change 
in predictor variable.   = change in standard deviation of dependent variable per 
change in standard deviation of predictor variable. 
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Table 3: Q2 multiple regression analyses. 
 Cognitive Functioning (n=92) Social Functioning (n=91) 
 Step 1 Step 2 Step 1 Step 2 
 B SE B  B SE B  B SE B  B SE B  
Age  0.01 0.03 0.06 0.00 0.03 0.02 0.47 0.51 0.12 0.40 0.51 0.10 
Employment 
status  
(not retired) 
-0.05 0.50 -0.01 -0.11 0.49 -0.03 -13.49 9.73 -0.18 -9.56 9.71 -0.13 
PMC -0.11 0.13 -0.09 -0.03 0.13 -0.03 -1.87 2.23 -0.08 -2.36 2.25 -0.10 
LTHP -0.09 0.10 -0.11 -0.09 0.10 -0.10 - - - - - - 
T1 Cognitive 
Functioning 
0.21 0.11 0.22 0.13 0.11 0.14 - - - - - - 
T1 Social 
Functioning 
- - - - - - 0.23 0.13 0.23 0.28 0.13 0.27* 
T1 Fatigue -0.01 0.01 -0.15 -0.01 0.01 -0.19 -0.19 0.15 -0.17 -0.16 0.15 -0.13 
Gender (Female) - - - - - - 13.06 5.95 0.22* 12.93 5.89 0.21* 
Quit smoking 
(versus Never) 
- - - -1.47 0.51 -0.47** - - - 10.49 9.57 0.17 
Current smoker 
(versus Never) 
- - - -1.43 0.57 -0.40* - - - -5.27 10.81 -0.07 
Quit smoking 
(versus Current) 
- - - -0.04 0.37 -0.01 - - - 15.76 7.22 0.25* 
 R2 =.15 (F=2.48)* R2 =.23 (F=3.10)** 
R2Change=.08* 
R2 =.25 (F=4.57)*** R2 =.29 (F=4.22)*** 
R2Change=.05 
Note: *p<.05, **p<.01, ***p<.001 
Abbreviations: LTHP= Long term health problems, PMC=previous medical 
conditions.  
Interpretation: B = a change in dependent variable (e.g., Coughing) per unit change 
in predictor variable.   = change in standard deviation of dependent variable per 
change in standard deviation of predictor variable. 
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Table 3: Q2 multiple regression analyses (continued).  
 
 Fatigue (n=92) 
 Step 1 Step 2 
 B SE B  B SE B  
Age  -0.15 0.43 -0.04 -0.06 0.44 -0.02 
Employment status  
(not retired) 
15.84 8.33 0.23 13.28 8.42 0.20 
PMC 0.66 1.96 0.03 0.48 2.01 0.02 
T1 Social Functioning 0.00 0.11 0.00 -0.02 0.11 -0.03 
T1 Fatigue 0.48 0.12 0.46*** 0.46 0.12 0.44*** 
Number of toxicities 6.00 3.30 0.17 6.48 3.28 0.18 
Quit smoking  
(versus Never) 
- - - 0.39 8.31 0.01 
Current smoker  
(versus Never) 
- - - 11.72 9.37 0.18 
Quit smoking  
(versus Current) 
- - - -11.33 6.32 -0.19 
 R2 =.33, (F=6.94)*** R2 =.36, (F=5.71)*** 
R2Change=.03 
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Figure 1: Recruitment and participation throughout the study.  
 
641 identified as eligible
5 declined to be approached
23 did not attend clinic 
309 inappropriate to approach
N = 304
consented to participate
n = 202 (68.2%) 
returned questionnaires
T1    
n=296
n = 114
returned questionnaires
8 withdrew
82 deceased
T2 
n=214
Total of 296:
38.5%
Total of 214:
53.3%
n=13 (6.1%) 
replied at T2 only.
n=13 (4.4%) 
replied at T2 only.
 
